Serabi Mining
SPECULATIVE BUYEx-hedge fund manager David Kingsman is backing bombed-out Brazil gold play Serabi Mining’s £2.4m refinancing.
Greenwood Investments, a vehicle controlled by Kingsman, has taken more than half of London-based Serabi’s £2.1m placing at 1.5p and has provided a further £300,000 facility in loan stock convertible into shares at the same price. The funding will give Greenwood and Kingsman together 29.3% of AIM-quoted Serabi, which is seeking to establish substantial reserves around its Palito mine in Brazil’s Jardim do Ouro (Garden of Gold) region.
The company, floated in 2005 at 30p, saw its shares reach 54.5p the following year, only to watch them collapse to a nearly invisible 0.43p after chairman Graham Roberts and chief executive Michael Hodgson decided to suspend underground mining there in 2008 because of delays in obtaining equipment and a lack of adequate working capital. Now, however, using the findings of a 6,000-hectare helicopter survey over Palito and its surroundings, the Serabi team argues further evaluation of 18 geological anomalies identified by the survey might yield a target of two-to-three ‘Palito look-alikes’ and establish a total reserve equivalent to up to 600,000 oz of gold, within a potential resource equivalent to 1.2m oz of gold.
Kingsman, a London fund manager for ten years and now running a family investment office in Munich, is not the only business figure to back Serabi’s hoped-for return from the grave. In March, Steven Poulton, founder and former boss of Ariana Resources, director of Stellar Diamonds and involved in several other sector plays, bought nearly 4% of Serabi at less than 1p.
The shares have now bounced to 2.03p, where they are a high-risk recovery punt.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £2.8m
PE Forecast: n/a
Share price: 2.03p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
